Virtual ASCO Conference reveals mesothelioma research on the cusp of several promising advances
At the end of May, in a brand new virtual format, the annual meeting for the American Society of Clinical Oncology (ASCO) was one of the first such meetings to take place since COVID-19 caused disruptions and cancellations across the board. Scientific meetings such as this one are an important venue where scientists and researchers report their newest finding among an audience of their peers.
“We are on the cusp of several promising advances being mature enough to get integrated into patient care. I am so thankful to the patients and families who participate in these trials as it is the only way to move this field forward,” said Dr. Marjorie G. Zauderer, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center and the chair of the Board of Directors of the Mesothelioma Applied Research Foundation.
Dr. Zauderer was a discussant in the session titled “Adding to Chemotherapy in Mesothelioma” discussing two studies, both of which examined the addition of agents beyond cytotoxic chemotherapy in the treatment of mesothelioma. The first study looked at the addition of an immunotherapeutic agent to standard chemotherapy in previously untreated patients. The second study looked at the addition of a VEGF inhibitor, ramucirumab, in previously treated patients.